Hey, on that note:
" but not all stocks are (or become) a CSL .."
Have you caught the excitement atm that is MSB Mesoblast? Stem Cell Biotech.
An ant compared to CSL, but a biotech 12 yrs of research in the making, at End Point now 2018 with 2 phase 3 results and 1 phase 2b result. 2019 one more phase 3 result. Commercialisation in any one of those could turn it peer comparison wise more so into say, a Sirtex SRX $1.5B MC (already being acquired.) If 3 or 4 out of 4, who knows, could be on the road ( long road ) onto the makings of a baby CSL.
